In April 1939, a dying man handed his son a desk and a set of keys. Charles Rudolph Walgreen Sr. , weakened by cancer and too ill to continue, had spent four decades building a pharmacy empire from a single storefront beneath Chicago’s elevated train line. His parting instruction was brief: here is your desk, here are the keys, I’m going fishing.
He died later that year, leaving behind nearly 500 stores and a family name that would become one of the most recognizable in America. But the empire he built to immortalize that name would eventually devour his own bloodline, pay billions for fueling the deadliest drug epidemic in American history, and end up in the hands of strangers who had no connection to the family at all. The founder’s journey began with an accident. In 1889, at sixteen, Charles Walgreen was working in a shoe factory in Dixon, Illinois, dreaming of a career in professional sports.
A heavy machine slammed down on his hand, severing the top joint of his his middle finger. His athletic ambitions died in that moment. The attending physician, noticing the young man’s meticulous nature during recovery, suggested a vocation that required precision rather than brute strength: pharmacy. Walgreen took the advice and arrived in Chicago in 1893, nearly destitute.
According to the family story, he was reduced to his last five cents. Rather than hoarding them, he spent two cents on a newspaper to search for work and tossed the remaining three cents into the Chicago River for luck. It was a gesture of pure defiance, a refusal to accept scarcity. By 1897 he earned his pharmacist registration.
Then war intervened. In 1898, swept up in patriotic fervor, he enlisted in the First Illinois Volunteer Cavalry and shipped to Cuba during the Spanish-American War. Assigned to a military hospital dispensary, he contracted both yellow fever and malaria simultaneously. His body shut down, and his name was placed on the official casualty list under the heading dead.
He woke up anyway. The fevers permanently compromised his health, leaving him with lingering symptoms that would plague him for the rest of his life, but the brush with death gave him an existential clarity: the window for building something lasting was finite. In 1901, with a $2,000 loan from his father and his own savings, the twenty-seven-year-old pharmacist purchased a small drugstore at the corner of Cottage Grove and Bowen Avenues on Chicago’s South Side. The store was just twenty feet wide and fifty feet deep.
The previous owner, Isaac Blood, was eager to unload it, viewing the working-class neighborhood as a dead end. Until the paternal loan was repaid, the business operated under a name that would later seem hauntingly prophetic: the Blood-Walgreens Drug Company. Walgreen immediately began dismantling the conventions of traditional retail. In the early 1900s, drugstores kept merchandise locked behind glass cases, treating customers with suspicion.
Walgreen dragged products into the open, creating bright displays that invited customers to browse and touch. He manufactured his own pharmaceutical line to bypass distributors and control quality and profit margins. When his soda fountain proved popular, he built his own ice cream factory on East 40th Street rather than buying from local vendors. By 1916 the company had nine stores and was formally incorporated.
By 1919 it counted twenty locations across Chicago. Then came Prohibition. In 1920, the Volstead Act, which banned alcohol, contained a provision that would prove commercially invaluable. Physicians could legally prescribe up to a pint of whiskey per person every ten days for medicinal purposes, and pharmacies were authorized to fill those prescriptions.
The range of ailments that miraculously qualified included influenza, diabetes, anxiety, and old age. Walgreen’s stores operated twenty stores before Prohibition. By 1929, that number had exploded to 525. Prohibition historian Daniel Okrent was direct about the driver: it is doubtful, he wrote, that milkshakes alone were responsible for that rocketing growth.
Decades later, the founder’s grandson, Cork Walgreen, recalled a family anecdote: his grandfather worried constantly about fires in his stores, yet also wanted the fire department in and out as fast as possible, because whenever the firemen came in, the store would mysteriously lose a case of liquor from the back. The company’s other famous innovation of that era was more benign. In 1922, a soda fountain employee named Ivar Pop Coulson took malted milk powder, originally invented as a nutritional supplement for infants and invalids, added milk, chocolate syrup, and two generous scoops of Walgreen’s own housemade vanilla ice cream. The result was the modern malted milkshake.
Customers lined up four deep within hours. The drink turned Walgreen’s stores into social destinations, gathering places for teenagers and families, and every cent of profit stayed in the company because Walgreen controlled the entire supply chain. Charles Walgreen Sr. stepped down in August 1939, too ill to continue.
He left behind 494 stores across thirty-seven states and approximately 12,000 employees. His successor, his son Charles R. Walgreen Jr. , ran the company for thirty-seven years, steering it through the transition to self-service retail.
He pioneered the open-floor pharmacy format that became the template for American drugstores, even canceling a planned merger with the Thrifty Drug Company of California in 1949 because their counter-service model was incompatible with his vision. The first crack in the dynasty appeared in April 1939, when the founder’s only daughter, Ruth, initiated divorce proceedings against her husband, Justin Whitlock Dart. Dart was a brilliant and ambitious outsider whom the founder had personally brought into the company and elevated to general manager. After the divorce, Dart was forced out by the family-backed board in November 1941.
He immediately joined United Drug Incorporated, seized control, and rebranded it as Rexall drugstores, becoming Walgreen’s most formidable competitor for the next four decades. The next generation took over in 1969, when Charles Walgreen III, known as Cork, became president. He had started at the bottom as a stock boy at sixteen, following the family doctrine that no heir could command the empire without understanding the front line. As CEO from 1971, Cork inherited a sprawling conglomerate distracted by restaurants, discount centers, aspirin factories, and travel agencies.
He liquidated the clutter and refocused the entire enterprise on one thing: the standalone drugstore on high-traffic American corners. He pioneered the pharmacy drive-thru window at national scale. The results were undeniable: twenty-three consecutive years of record sales and earnings. Under his leadership, sales grew from $817 million to $13 billion, and market capitalization from $164 million to $19 billion.
But while Cork built his corporate fortress, his family was crumbling. Tad Walgreen, born Charles Alexander Walgreen, one of Cork’s six sons from a first marriage, grew up estranged from his father. He struggled with alcoholism and, in the late 1980s, met a woman named Lauren while both were in rehabilitation. They married, had two children, and descended together into addiction.
Tad served time at Joliet Penitentiary for drunk driving. At the time of his death, he was facing criminal exposure for prescription forgery, having been caught trying to obtain narcotic painkillers from the pharmacy counters of his own family’s stores. In the spring of 1996, at age thirty-six, Tad died of a cocaine overdose in a modest apartment in Berkeley, Illinois, forty miles from where his grandfather was still affiliated with the company’s board. Lauren died of a drug overdose three years later, at age thirty-one.
After Tad’s death, Cork and his wife legally adopted Tad’s children. In a Cook County courtroom, Cork described visiting Tad and Lauren’s apartment: waste and soiled clothes strewn about, dirty cookware encrusted with grime, a gaping hole punched in a wall. The family’s presence in the company ended quietly. Kevin Walgreen, Cork’s son and the last family member in management, resigned in January 2009.
Cork retired from the board in 2010. A 2014 SEC filing noted that there were no family relationships among any of the directors or executive officers. The name on the stores had become a marketing asset, a registered trademark completely untethered from the bloodline that created it. The boardroom vacuum was filled by a new breed of global financial operators, dominated by Stefano Pessina, an Italian nuclear engineer turned pharmaceutical distributor.
Over four decades, Pessina executed more than 1,000 acquisitions across Europe. In 2007, partnering with private equity firm KKR, he took the British pharmacy chain Boots private in a $22. 3 billion leveraged buyout, the largest in European history. In 2012, Walgreens CEO Greg Wasson initiated a two-step acquisition of Pessina’s Alliance Boots empire.
The American executives were outmatched. A deputy in Pessina’s inner circle dismissed them with a chilling summary: men against boys. In 2014, activist hedge funds demanded Walgreens execute a tax inversion, relocating its headquarters to Switzerland to capture an estimated $4 billion in tax savings. President Barack Obama publicly condemned corporate inversions.
Illinois Senator Dick Durbin warned the CEO that the patriotic customer base would reject a pharmacy chain that abandoned the United States. On August 6, 2014, Wasson announced Walgreens would remain an American corporation. Wall Street retaliated: the stock plummeted 14 percent in a single day, wiping out billions in market value. On December 31, 2014, Walgreens Boots Alliance was formally constituted.
Pessina emerged holding $11. 3 billion in stock and seized the CEO position. Wasson was ousted. The American executives were purged and replaced by European managers.
Cork Walgreen died on September 26, 2016. His eulogy was delivered by a former Boots executive. The new management’s pursuit of profit soon produced a catastrophic reckoning. Between 2012 and 2023, Walgreens pharmacists filled millions of prescriptions for controlled substances that the Department of Justice would later describe as unlawful: opioids in excessive quantities, prescriptions filled before prior supplies were exhausted, and the deadly combination of an opioid, a benzodiazepine, and a muscle relaxant.
Leaked internal emails revealed executives complaining that safety checks were taking too much time and hurting controlled substance sales. Pharmacists were prevented from warning each other about dangerous prescribers through the shared computer system. In some cases, the DOJ noted, patients died shortly after filling these unverified combinations at Walgreens locations. In 2022, the company agreed to pay approximately $5.
7 billion to states and local governments. Aggregate opioid liabilities pushed toward $6 billion. Meanwhile, a separate crisis was eroding the business. Market capitalization peaked at nearly $92 billion in 2015.
A costly pivot into healthcare services failed. Insurance companies slashed reimbursement rates. Retail theft forced stores to lock everyday items behind plexiglass. Patients migrated to Amazon Pharmacy, which captured the high-margin chronic medication market.
In February 2024, Walgreens was removed from the Dow Jones Industrial Average, replaced by Amazon. By late 2024, the company suspended its 92-year-old dividend and announced the closure of 1,200 underperforming stores. Combined net losses across 2023 and 2024 exceeded $11. 7 billion.
The corporation even sued the founder’s own descendants. In 2013, it sued great-grandson Charles R. Walgreen to stop his cell phone accessories business, IWAG. In 2023, when he tried to launch a new venture called Walgreens Health Solutions, the corporation sued him again for trademark infringement.
The court ruled that the corporate entity had spent a century making the name Walgreens so synonymous with its stores that it overpowered the great-grandson’s right to use his own family name in business. On August 28, 2025, Walgreens Boots Alliance was delisted from the NASDAQ and taken private by Sycamore Partners. The acquisition price was approximately $10 billion in equity value, or $23. 7 billion including debt.
The empire was immediately broken into five separate companies. The new CEO, Mike Motz, had previously overseen the closure of one-third of all US Staples stores as a Sycamore executive. Stefano Pessina, then eighty-three, reinvested a significant stake and would command nearly 50 percent of the Boots division. The founder’s journey had begun with a $6,000 investment in 1901.
His son ran the company for thirty-seven years. His grandson grew it to $19 billion in annual sales. His great-grandson died of an overdose in a modest apartment while facing charges for forging prescriptions at his own family’s pharmacies. The family was removed from governance by 2009, from the board by 2010, and from any commercial use of its own name by 2025.
No one named Walgreen runs Walgreens anymore. The stores still bear the founder’s surname, but they belong to a private equity firm, a faceless entity whose treatment of the business has been guided not by the founder’s vision, but by the cold mechanics of leverage and return. The name that once stood for a family’s pride remains on the doors, but the family itself has become a ghost in the machine it built.